[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$f9oQPAvNYMW5hDnaHC7XpLB_tdogwzJWaDHMV1-sK3k8":8,"$fxYddBWEbmSy0HDw6VrUO5lAdHleta6ZtFspzHIikeDw":55,"$f_KmijhvFkK11H5LmaKtSwpKd9wS-NKb58caOt2SgYes":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},74124,871233,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//5RpA5Ec5bNgdWCwdZCSze9XOoeKKQal7.png","蔡景川","北大荒集团建三江医院","肿瘤科","住院医师",80,0,"肝恶性肿瘤3期治疗全解析：实用指南与药物选择","","https://ystcdn.venuertc.com/venue/AI/4db52eef-cbbe-4238-870c-25e74c6dd2ca.jpg","\u003Cdiv class=\"material-wrapper\">\n  \u003Ch1 id=\"material_title\" class=\"material-title\">肝恶性肿瘤3期治疗全解析：实用指南与药物选择\u003C/h1>\n  \n  \u003C!-- 引入主题说明 -->\n  \u003Cdiv class=\"material-intro material-bg\">\n    \u003Cp>在肿瘤科治疗过程中，针对肝恶性肿瘤3期，药品的选择与使用细节至关重要。不论是静脉补液、电解质平衡，还是化疗和靶向药物，每种药品都有自己的“正确打开方式”。本文将帮你梳理 \u003Cb>7大关键用药细节\u003C/b>，使你在实际操作时信心十足、更安全有效。\u003C/p>\n  \u003C/div>\n  \n  \u003C!-- 01 服用时间和方法 -->\n  \u003Csection class=\"material-section\">\n    \u003Ch2 class=\"material-subtitle material-bg\">01 服用时间和方法🕒\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cp>肝恶性肿瘤3期治疗涉及多种给药途径：口服、静脉注射、甚至皮下注射。比如营养支持液体和电解质制剂，一般要求 \u003Cb>按医嘱分时段静脉滴注\u003C/b>，避免一次性大量输入。\u003C/p>\n      \u003Cul>\n        \u003Cli>口服化疗药：如索拉非尼，建议整片吞服，餐前餐后均可，但应保持规律。\u003C/li>\n        \u003Cli>静脉药物：例如奥沙利铂等，常在化疗室操作，滴注速度需控制，每次注射时间通常为2-6小时。\u003C/li>\n        \u003Cli>服用方法应根据药品说明书，特殊要求需严格遵守，不可自行更改用药时间。\u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"material-tip\">\n        \u003Cspan class=\"material-tip-emoji\">💡\u003C/span>\n        \u003Cb>正确做法：\u003C/b>遇到含有肠溶包衣的药片，必须整片吞服；静脉药品使用时，须由专业护理人员严格监控滴速。\u003Cbr>\n        \u003Cb>补充说明：\u003C/b>临床上有患者未按分时滴注营养液，导致静脉反应加重，提醒务必遵循分时原则。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 02 剂型特点和服用技巧 -->\n  \u003Csection class=\"material-section\">\n    \u003Ch2 class=\"material-subtitle material-bg\">02 剂型特点和服用技巧 💊\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cp>肝恶性肿瘤相关药品有片剂、注射液、乳剂等；每种剂型使用方式不尽相同。例如，奥沙利铂为注射液剂型，须严格控制稀释浓度，避免不良反应。肠溶片必须整片吞服，防止胃酸降解药效，乳剂用药则需均匀摇匀后用。\u003C/p>\n      \u003Cul>\n        \u003Cli>片剂和胶囊：不可随意掰开、咀嚼；特殊剂型需遵循说明书。\u003C/li>\n        \u003Cli>注射剂型：必须由专科护士操作，避免推注过快。\u003C/li>\n        \u003Cli>乳剂及悬液类：使用前摇匀，防止药物分层。\u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"material-tip\">\n        \u003Cspan class=\"material-tip-emoji\">✨\u003C/span>\n        \u003Cb>需要注意：\u003C/b>在服用肠溶片和悬液剂型时，建议用200 ml温水送服，增强吸收效果。\u003Cbr>\n        \u003Cb>案例提醒：\u003C/b>一位患者服用肝保护肠溶片期间，误将药片掰开后服用，导致药效骤减并出现胃部不适。因此，特殊剂型绝对不能掰碎或嚼服。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 03 药物相互作用 -->\n  \u003Csection class=\"material-section\">\n    \u003Ch2 class=\"material-subtitle material-bg\">03 药物相互作用 🔄\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cp>肝恶性肿瘤3期治疗常用药物如索拉非尼、奥沙利铂、胃黏膜保护剂、补液和电解质制剂等，存在一定相互作用。尤其在多种药品联合使用时，容易产生协同或拮抗反应。\u003C/p>\n      \u003Cul>\n        \u003Cli>索拉非尼与酮类、酸类药物同服，可能影响肝酶代谢，增加毒性反应。\u003C/li>\n        \u003Cli>奥沙利铂避免与钙镁溶液混合滴注，否则疗效降低。\u003C/li>\n        \u003Cli>补液时，不宜与静脉抗生素混合；电解质类药品须分次滴注，避免与强酸类药物同时使用。\u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"material-tip\">\n        \u003Cspan class=\"material-tip-emoji\">⚠️\u003C/span>\n        \u003Cb>正确做法：\u003C/b>遇到需联用多种药物时，务必按照分开时间顺序服用，至少间隔30-60分钟，尤其是静脉滴注药物。\n      \u003C/div>\n      \u003Cp>临床数据表明，索拉非尼合并用药导致肝酶升高率可达15%（Cheng et al., 2009）。合理避开高风险相互作用，能显著提升用药安全性。\u003C/p>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 04 特殊人群用药调整 -->\n  \u003Csection class=\"material-section\">\n    \u003Ch2 class=\"material-subtitle material-bg\">04 特殊人群用药调整 👨‍👩‍👧‍👦\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cp>不同年龄和生理状况患者，用药剂量及方式需调整：\u003C/p>\n      \u003Cul>\n        \u003Cli>老年患者：肝肾功能下降，化疗药物常须减量。索拉非尼用量需个体化调整。\u003C/li>\n        \u003Cli>儿童：极少使用化疗药品，如确需应用，剂量按体重、体表面积精确计算，避免不良反应。\u003C/li>\n        \u003Cli>孕妇、哺乳期：涉及奥沙利铂、索拉非尼等应避免使用，推荐选用安全性高的支持类药品，除非医生权衡利弊后决定。\u003C/li>\n        \u003Cli>肝、肾功能不全者：所有化疗和靶向药物类均需减量或改用，避免药物蓄积造成毒性。\u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"material-tip\">\n        \u003Cspan class=\"material-tip-emoji\">🔍\u003C/span>\n        \u003Cb>特别提醒：\u003C/b>老年患者调整剂量时需严密监测肝肾代谢指标，避免药物蓄积；孕妇用药必须医生指导！\u003Cbr>\n        \u003Cb>临床案例：\u003C/b>一位70岁老年患者使用索拉非尼时，起始剂量减半，未发生明显不良反应，表明剂量调整对特殊人群极为重要。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 05 常见不良反应及处理 -->\n  \u003Csection class=\"material-section\">\n    \u003Ch2 class=\"material-subtitle material-bg\">05 常见不良反应及处理 🚨\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cp>肝恶性肿瘤3期治疗相关药物的不良反应并不少见。常见药品如索拉非尼、奥沙利铂、胃黏膜保护剂等，副作用各异：\u003C/p>\n      \u003Cul>\n        \u003Cli>索拉非尼：说明书提示，胃肠反应发生率约为30%，皮疹发生率约为10%。\u003C/li>\n        \u003Cli>奥沙利铂：手足麻木、静脉刺激反应，发生率约为25%（Douillard et al., 2000）。\u003C/li>\n        \u003Cli>电解质制剂：偶有低钾或高钠症，需监测血电解质。\u003C/li>\n        \u003Cli>胃黏膜保护剂：罕见发生便秘、腹胀等。\u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"material-tip\">\n        \u003Cspan class=\"material-tip-emoji\">🚑\u003C/span>\n        \u003Cb>正确做法：\u003C/b>一旦出现症状，应暂停相关药品，立刻报告医护人员，并根据症状给予对症处理。如服药后出现皮疹、胃肠反应，及时停药并调整给药方案。\n      \u003C/div>\n      \u003Cp>临床研究显示，联合用药不良反应发生率提升约8%（Llovet et al., 2008），因此每次用药后要留意新出现的身体反应。\u003C/p>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 06 储存条件和有效期 -->\n  \u003Csection class=\"material-section\">\n    \u003Ch2 class=\"material-subtitle material-bg\">06 储存条件和有效期 ⏳\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cp>大多数肝恶性肿瘤专用药品，需要在阴凉干燥处密闭储存，避免高温潮湿环境导致药品失效。例如：\u003C/p>\n      \u003Cul>\n        \u003Cli>片剂/胶囊：常温（15-25℃）避光保存，开瓶后1个月内用完。\u003C/li>\n        \u003Cli>注射液：冷藏（2-8℃），开启后24小时内必须用完，超时丢弃。\u003C/li>\n        \u003Cli>悬液/乳剂：摇匀后使用，开封后一周内使用完毕。\u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"material-tip\">\n        \u003Cspan class=\"material-tip-emoji\">📦\u003C/span>\n        \u003Cb>正确做法：\u003C/b>药品要单独存放，远离儿童。过期药品或变色变味药品不可再用，应妥善丢弃。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 07 漏服和过量处理 -->\n  \u003Csection class=\"material-section\">\n    \u003Ch2 class=\"material-subtitle material-bg\">07 漏服和过量处理 📝\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cp>肝恶性肿瘤3期治疗药品因方案复杂，偶有漏服或过量情况：\u003C/p>\n      \u003Cul>\n        \u003Cli>片剂类如索拉非尼漏服时：发现后尽快补服一次，但不可双倍剂量。\u003C/li>\n        \u003Cli>静脉注射药物漏滴：请及时通知医护，由专人评估补药方案。\u003C/li>\n        \u003Cli>若因不慎过量服用药物：出现异常症状应立即就医，伴有严重反应需携带用药记录。\u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"material-tip\">\n        \u003Cspan class=\"material-tip-emoji\">🛑\u003C/span>\n        \u003Cb>正确做法：\u003C/b>药品按时规律使用，不得随意增减剂量！任何一次漏服或过量都应该主动报告医生或护士，绝不自行处理。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 药品特点简要总结 -->\n  \u003Csection class=\"material-section material-bg\">\n    \u003Ch2 class=\"material-summary-title\">结语与重点强调\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cp>无论是口服药、注射剂还是支持性药品，用药安全始终在第一位。牢记剂型特点、合理调整时间剂量、重视药物相互作用，能显著降低风险，提高治疗效果。此外，不良反应识别、药品储存、漏服和过量处理，也是安全用药的关键环节。\u003C/p>\n      \u003Cul>\n        \u003Cli>最重要注意事项：\u003Cb>剂型不可随意掰碎\u003C/b>，多药联合需严格分开服用。\u003C/li>\n        \u003Cli>发现不良反应要随时报告，无故增减剂量极易出事故。\u003C/li>\n      \u003C/ul>\n      \u003Cp>不管你是患者本人还是家属，都应该按照上文细节精准执行，争取最大化药品疗效和安全性。如果遇到任何疑问，\u003Cb>请及时咨询专业医药人员\u003C/b>。\u003C/p>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 文献引用区域 -->\n  \u003Csection class=\"material-section\">\n    \u003Ch2 class=\"material-ref-title\">参考文献\u003C/h2>\n    \u003Cdiv class=\"material-ref\">\n      \u003Col>\n        \u003Cli>Cheng, A. L., Kang, Y. K., Chen, Z., et al. (2009). Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. \u003Ci>Lancet Oncology, 10\u003C/i>(1), 25-34.\u003C/li>\n        \u003Cli>Douillard, J. Y., Cunningham, D., Roth, A. D., et al. (2000). Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. \u003Ci>Lancet, 355\u003C/i>(9209), 1041-1047.\u003C/li>\n        \u003Cli>Llovet, J. M., Ricci, S., Mazzaferro, V., et al. (2008). Sorafenib in advanced hepatocellular carcinoma. \u003Ci>New England Journal of Medicine, 359\u003C/i>(4), 378-390.\u003C/li>\n      \u003C/ol>\n    \u003C/div>\n  \u003C/section>\n\u003C/div>\n\n\u003Cstyle>\n.material-wrapper {\n  font-family: Helvetica, Arial, 'Microsoft YaHei', sans-serif;\n  background: #fc;\n  color: #222;\n  max-width: 820px;\n  margin: 60px auto 40px auto;\n  padding: 20px 32px 32px 32px;\n  border-radius: 14px;\n  box-shadow: 0px 6px 18px rgba(120,120,140,0.07);\n  box-sizing: border-box;\n}\n.material-title {\n  font-size: 2.3em;\n  text-align: left;\n  font-weight: 700;\n  margin-bottom: 35px;\n  padding-bottom: 5px;\n  letter-spacing: 2px;\n  color: #2c4849;\n  border-bottom: 2px solid #e1e7ea;\n}\n.material-section {\n  margin-bottom: 44px;\n  border-radius: 10px;\n  box-sizing: border-box;\n}\n.material-bg {\n  background: linear-gradient(90deg, #e3f3f7 15%, #f8fafb 100%);\n  padding: 22px 20px 22px 25px;\n  border-radius: 10px;\n}\n.material-subtitle {\n  font-size: 1.6em;\n  font-weight: 600;\n  color: #3c9c9c;\n  margin: 0px 0px 18px 0px;\n  border-left: 8px solid #bee8ee;\n  padding-left: 12px;\n  background: linear-gradient(90deg,#e8f2ed 40%,#f0f4f5 95%);\n  letter-spacing: 1px;\n  border-radius: 6px;\n  box-sizing: border-box;\n}\n.material-content {\n  font-size: 1.13em;\n  padding: 10px 10px 10px 5px;\n  line-height: 2;\n  margin-bottom: 5px;\n}\n.material-content ul {\n  margin: 10px 0 15px 24px;\n  padding: 0 0 0 9px;\n}\n.material-content li {\n  margin-bottom: 7px;\n  font-size: 1em;\n}\n.material-tip {\n  background: linear-gradient(90deg,#ebfaff 55%,#fcfefe 100%);\n  border-left: 5px solid #90dae0;\n  border-radius: 7px;\n  padding: 18px 14px 12px 18px;\n  margin: 20px 0;\n  box-sizing: border-box;\n  box-shadow: 0 2px 10px rgba(125,185,207,0.04);\n  font-size: 0.98em;\n  position: relative;\n}\n.material-tip-emoji {\n  font-size: 1.3em;\n  vertical-align: middle;\n  margin-right: 7px;\n}\n.material-summary-title {\n  font-size: 1.4em;\n  font-weight: 600;\n  color: #356d6e;\n  margin-bottom: 16px;\n  margin-top: 20px;\n  letter-spacing: 1px;\n}\n.material-ref-title {\n  font-size: 1.18em;\n  color: #618b8f;\n  margin-bottom: 17px;\n  margin-top: 0px;\n  font-weight: bold;\n  letter-spacing: 1px;\n}\n.material-ref ol {\n  padding-left: 18px;\n  font-size: 0.98em;\n  color: #437476;\n}\n.material-ref li {\n  margin-bottom: 10px;\n  line-height: 1.7;\n}\n@media (max-width: 600px) {\n  .material-wrapper {\n    padding: 7px 7px 20px 7px;\n    max-width: 96%;\n  }\n  .material-title {\n    font-size: 1.35em;\n    margin-bottom: 19px;\n  }\n  .material-section {\n    padding: 2px;\n    margin-bottom: 24px;\n  }\n  .material-subtitle {\n    font-size: 1.13em;\n    margin-bottom: 7px;\n  }\n  .material-bg {\n    padding: 12px 7px 7px 9px;\n  }\n}\n\u003C/style>","\u003Cdiv class=\"material-wrapper\">\n  \u003Ch1 id=\"material_title\" class=\"material-title\">肝恶性肿瘤3期治疗全解析：实用指南与药物",516,"2025-11-26 00:22:33","肝恶性肿瘤, 治疗, 药物选择, 用药指导, 不良反应, 药物相互作用, 特殊人群, 药品储存","全面解析肝恶性肿瘤3期的治疗方案，提供7大关键用药细节，确保患者和家属可安全有效地选择药物，实现更好的治疗效果。","2025-12-05 00:00:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]